Answers are grounded in this paper and cite their sources.
Truncating mutations in the adenomatous polyposis coli (APC) gene-a key driver of colorectal cancer (CRC) initiation-frequently lead to the production of a truncated APC protein (Trunc-APC). However, its post-transcriptional roles and oncogenic potential remain largely unexplored. Here, we demonstrate that Trunc-APC functions as an RNA-binding protein, directly associating with pre-mRNA via its N-terminal 1-169 amino acid region to regulate widespread alternative splicing (AS) in CRC cells. Specifically, Trunc-APC promotes exon inclusion in ARHGEF11, producing an oncogenic isoform that is associated with enhanced Bcl-xL/BAX complex formation and reduced apoptosis. Mechanistically, Trunc-APC interacts with the RNA helicase DDX21 and facilitates SF3B complex recruitment to pre-mRNA, thereby modulating splicing patterns. Notably, treatment with the splicing inhibitor Madrasin significantly reduced tumor burden in ApcMin/+ CRC mice, indicating strong antitumor efficacy. Collectively, these findings establish Trunc-APC as a novel regulator of alternative splicing and a promoter of CRC progression, and highlight the therapeutic potential of targeting the Trunc-APC/DDX21/SF3B axis in CRC.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: